SCHEMBL2371771

SCHEMBL2371771

CNS(=O)(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.63
LMNA P02545 1/20 0.63
HTT P42858 1/20 0.63
FFAR4 Q5NUL3 2/20 0.60
GAA P10253 1/20 0.52
ALDH1A1 P00352 1/20 0.52
KIF11 P52732 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA13 Q8N1Q1 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
HDAC1 Q13547 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16060627 0.82 FFAR4 (0.57) SMN1; SMN2LMNAFFAR4ALDH1A1KIF11
SCHEMBL2371770 0.81 FFAR4 (0.56) SMN1; SMN2FFAR4KIF11HDAC1HDAC8
SCHEMBL419333 0.81 FFAR4 (0.56) SMN1; SMN2FFAR4ALDH1A1KIF11HDAC1
SCHEMBL8012671 0.81 FFAR4 (0.56) SMN1; SMN2FFAR4KIF11CA12CA1
SCHEMBL5608290 0.81 FFAR4 (0.56) SMN1; SMN2LMNAFFAR4ALDH1A1KIF11
SCHEMBL13412196 0.81 FFAR4 (0.56) SMN1; SMN2LMNAFFAR4ALDH1A1KIF11
SCHEMBL19629835 0.80 FFAR4 (0.52) FFAR4KIF11CA1CA2HDAC1
SCHEMBL4572470 0.80 SLC6A4 (0.51) SMN1; SMN2LMNAHTTFFAR4
SCHEMBL3684870 0.80 CA12 (0.58) SMN1; SMN2LMNAFFAR4ALDH1A1CA12
SCHEMBL7587082 0.80 FFAR4 (0.71) SMN1; SMN2FFAR4KIF11HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547204-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS Bayer Intellectual Property GmbH (DE) 2013-01-23 EP claimed
US-20110230350-A1 ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 US claimed
WO-2011113861-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 WO claimed
CN-116806217-A Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof 拉帕塔疗法公司 2023-09-26 CN disclosed
WO-2023023594-A9 2‑DIARYLMETHYL‑4‑AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS ATUX ISKAY LLC (US) 2023-06-08 WO disclosed
WO-2023023594-A1 2‑DIARYLMETHYL‑4‑AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS ATUX ISKAY LLC (US) 2023-02-23 WO disclosed
EP-3347355-B1 HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS ICAHN SCHOOL MED MOUNT SINAI (US) 2022-07-13 EP disclosed
CN-110857278-B Method for synthesizing N-methylsulfonamide in water 南京理工大学 2022-04-15 CN disclosed
CN-109420525-B Metal iridium catalyst of 2, 2' -bis-benzimidazole ligand and method for synthesizing N-methylated primary amine by using metal iridium catalyst 南京理工大学 2021-10-08 CN disclosed
CN-110857278-A Method for synthesizing N-methylsulfonamide in water 南京理工大学 2020-03-03 CN disclosed
CN-109420525-A The method of the metal iridium catalyst and its synthesis N- methylation primary amine of 2,2 '-bisbenzimidazole ligands 南京理工大学 2019-03-05 CN disclosed
CN-103172523-A Method for realizing selective N-methylation of primary amine UNIV NANJING SCIENCE & TECH 2013-06-26 CN disclosed
EP-2547204-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS Bayer Intellectual Property GmbH (DE) 2013-01-23 EP disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
US-20110230350-A1 ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 US disclosed
WO-2011113861-A2 ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2011-09-22 WO disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed
EP-1521746-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2005-04-13 EP disclosed
WO-2003076418-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA SMN1; SMN2 4237/4885LMNA 4381/4885HTT 4317/4885
US-20110230350-A1 ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS STS, ARSA, TST SMN1; SMN2 4603/4885LMNA 4502/4885HTT 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.